Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles
- Conditions
- Infertility, Female
- Interventions
- Drug: highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metforminDrug: highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Menoufia University
- Target Recruit Count
- 176
- Registration Number
- NCT05362799
The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy
- Conditions
- Abortion in First Trimester
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- KK Women's and Children's Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT05341817
- Locations
- 🇸🇬
KK Women's and Children's Hospital, Singapore, Singapore
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
- Conditions
- Endometrial NeoplasmsAtypical Endometrial HyperplasiaProgesterone Resistance
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Xiaojun Chen
- Target Recruit Count
- 80
- Registration Number
- NCT05316935
- Locations
- 🇨🇳
Tenth People's Hospital of Tongji University, Shanghai, Shanghai, China
🇨🇳Obstetrics and Gynecology Hospital, Fudan University, Shanghai, Shanghai, China
Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Calcutta National Medical College and Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05304273
- Locations
- 🇮🇳
Calcutta National Medical College and Hospital, Kolkata, West Bengal, India
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
- Conditions
- Breast CancerSolid Tumors
- Interventions
- Drug: PF-07220060 + PF-07104091 combination dose escalation
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT05262400
- Locations
- 🇺🇸
Administrative Address: UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
- Conditions
- Endometrial Neoplasm Malignant Stage I
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 104
- Registration Number
- NCT05247268
- Locations
- 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China
SMMART Adaptive Clinical Treatment (ACT) Trial
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Biological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab Emtansine
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
- Conditions
- Head and Neck CancerBreast Cancer
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT05226871
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Science, Beijing, China
🇺🇦Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council, Dnipro, Ukraine
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
- Conditions
- HypogonadismHypogonadism, MaleHypogonadotropic Hypogonadism
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 8
- Registration Number
- NCT05205837
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation
- Conditions
- Polycystic Ovary SyndromeInfertilityPCOS
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Rachel Mejia
- Target Recruit Count
- 190
- Registration Number
- NCT05206448
- Locations
- 🇺🇸
University of Iowa Hospitals & Clinics- West Des Moines Clinic, West Des Moines, Iowa, United States
🇺🇸University of Wisconsin, Madison, Wisconsin, United States
🇺🇸University of Iowa Hospitals & Clinics - Davenport Clinic, Davenport, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.